PL2254869T3 - Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40 - Google Patents

Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40

Info

Publication number: PL2254869T3
Authority: PL; Poland
Prior art keywords: cx3cr1; neue; und; benzyl; expression
Prior art date: 2008-03-07

Application number

PL09717638T

Other languages

English (en)

Inventor

Angelo Guglielmotti

Guido Furlotti

Giorgina Mangano

Nicola Cazzolla

Barbara Garofalo

Original Assignee

Acraf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-07

Filing date

2009-03-05

Publication date

2017-10-31

2009-03-05 Application filed by Acraf filed Critical Acraf

2017-10-31 Publication of PL2254869T3 publication Critical patent/PL2254869T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Immunology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Dermatology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)

PL09717638T 2008-03-07 2009-03-05 Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40 PL2254869T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08425139		2008-03-07
EP09717638.2A EP2254869B1 (en)	2008-03-07	2009-03-05	Neue 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 und p40
PCT/EP2009/052585 WO2009109613A2 (en)	2008-03-07	2009-03-05	Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40

Publications (1)

Publication Number	Publication Date
PL2254869T3 true PL2254869T3 (pl)	2017-10-31

Family

ID=39671487

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL09718467T PL2254870T3 (pl)	2008-03-07	2009-03-05	Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1
PL09717638T PL2254869T3 (pl)	2008-03-07	2009-03-05	Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL09718467T PL2254870T3 (pl)	2008-03-07	2009-03-05	Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1

Country Status (25)

Country	Link
US (3)	US7919518B2 (pl)
EP (3)	EP3181551A1 (pl)
JP (2)	JP5509099B2 (pl)
KR (2)	KR101581828B1 (pl)
CN (2)	CN101952256B (pl)
AR (2)	AR070811A1 (pl)
AU (2)	AU2009221083B2 (pl)
BR (2)	BRPI0907976A2 (pl)
CA (2)	CA2712403C (pl)
CY (2)	CY1117584T1 (pl)
DK (2)	DK2254870T3 (pl)
EA (2)	EA018241B1 (pl)
ES (2)	ES2637009T3 (pl)
GE (2)	GEP20135912B (pl)
HR (2)	HRP20171208T1 (pl)
HU (1)	HUE027098T2 (pl)
IL (3)	IL206893A0 (pl)
LT (1)	LT2254869T (pl)
MX (2)	MX2010009623A (pl)
PL (2)	PL2254870T3 (pl)
PT (1)	PT2254869T (pl)
SG (1)	SG188177A1 (pl)
SI (2)	SI2254869T1 (pl)
UA (2)	UA105170C2 (pl)
WO (2)	WO2009109613A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2753149T3 (es) *	2008-03-07	2020-04-07	Acraf	Derivados de 1-bencil-3-hidroximetilindazol y utilización de los mismos en el tratamiento de enfermedades basadas en la expresión de MCP-1, CXCR1 y P40
KR101581828B1 (ko) *	2008-03-07	2015-12-31	아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이	신규한 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1, ｃｘ3ｃｒ1 및 ｐ40의 발현을 기초로 한 질환들의 치료에서 이의 용도
MX2010009624A (es)	2008-03-07	2010-09-28	Acraf	Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
EA019672B1 (ru) *	2009-08-03	2014-05-30	Ацьенде Кимике Рьюните Анджелини Франческо A.K.P.A.Ф. С.П.А.	Способ получения 1-бензил-3-гидроксиметил-1н-индазола и его производных и необходимые промежуточные соединения, содержащие магний
UA108742C2 (uk)	2009-09-23	2015-06-10		Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
EP2844250B1 (en) *	2012-05-01	2017-11-08	Translatum Medicus Inc.	Methods for treating and diagnosing blinding eye diseases
US8999292B2 (en)	2012-05-01	2015-04-07	Translatum Medicus Inc.	Methods for treating and diagnosing blinding eye diseases
MX347615B (es) *	2012-05-18	2017-05-04	Sanofi Sa	Derivados de pirazol y su uso como antagonistas de lpar5.
WO2013171316A1 (en)	2012-05-18	2013-11-21	Sanofi	Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
TWI653988B (zh)	2012-11-09	2019-03-21	Howard University	用於牙齒琺瑯質保護之嵌段共聚物
JP6625064B2 (ja) *	2014-05-15	2019-12-25	トランスレイタムメディカスインコーポレイテッド	眼障害を治療かつ診断するための組成物および方法
CN107635404B (zh) *	2015-06-12	2021-09-28	威特瑞有限公司	用于治疗疾病的mct4抑制剂
WO2016203313A1 (en) *	2015-06-16	2016-12-22	Translatum Medicus, Inc.	Compositions and methods for treating and diagnosing ocular disorders
CN110114351B (zh)	2016-12-12	2022-09-20	维托尔股份有限公司	Mct4的杂环抑制剂
GB201811169D0 (en)	2018-07-06	2018-08-29	Kancera Ab	New compounds
WO2020026471A1 (ja) *	2018-07-31	2020-02-06	株式会社親広産業	グルコース消費促進剤および解糖系促進剤
JP6612004B1 (ja) *	2018-07-31	2019-11-27	株式会社親広産業	グルコース消費促進剤および解糖系促進剤
CA3144861A1 (en)	2019-06-25	2020-12-30	Translatum Medicus, Inc.	Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
CN113929627A (zh) *	2021-10-19	2022-01-14	吕梁学院	一种宾达利的合成方法
WO2024108386A1 (zh) *	2022-11-22	2024-05-30	中国科学院深圳先进技术研究院	抗mcp1中和抗体在制备治疗神经退行性疾病引起的系统性炎症药物中的应用
WO2024165925A1 (en) *	2023-02-10	2024-08-15	Translatum Medicus Inc.	Bindarit conjugates, compositions and methods for treating ocular diseases or disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US416359A (en) *		1889-12-03		Sash-fastener
US364371A (en) *		1887-06-07		peice
IT1230441B (it) *	1989-02-07	1991-10-23	Acraf	Eteri della serie dell'indazolo
IT1253703B (it) *	1991-04-22	1995-08-23	Angelini Francesco Ist Ricerca	Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1293795B1 (it) *	1997-07-28	1999-03-10	Angelini Ricerche Spa	Farmaco attivo nel ridurre la produzione di proteina mcp-1
AU781849C (en)	1999-06-17	2006-03-02	Synta Pharmaceuticals Corp.	Inhibitors of IL-12 production
EP1199074A1 (en)	2000-09-15	2002-04-24	Warner-Lambert Company	Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en)	2000-09-15	2002-03-20	Warner-Lambert Company	Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
ATE417617T1 (de)	2001-03-15	2009-01-15	Seikagaku Kogyo Co Ltd	Mittel zur steurung der expression von il-12
MXPA04005181A (es)	2001-11-30	2005-06-17	Synta Pharmaceuticals Corp	Compuestos de pirimidina.
BRPI0415050A (pt)	2003-10-07	2006-11-28	Astrazeneca Ab	composto, formulação farmacêutica, método para tratar ou reduzir risco de uma doença ou condição humanas, uso de um composto ou de um sal deste farmaceuticamente aceitável, e, processo para a preparação de um composto ou de um sal deste farmaceuticamente aceitável
EP1806145B1 (en) *	2004-10-29	2017-08-16	Eisai R&D Management Co., Ltd.	Remedy for inflammatory diseases
JP2008519850A (ja)	2004-11-10	2008-06-12	シンタファーマシューティカルズコーポレーション	Ｉｌ−１２調節化合物
JP2008520712A (ja)	2004-11-19	2008-06-19	シンタファーマシューティカルズコーポレーション	ピリミジン化合物及びその使用
UA90707C2 (en)	2005-04-06	2010-05-25	Астразенека Аб	Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es)	2005-04-06	2007-05-02	Astrazeneca Ab	Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
MX2010009624A (es)	2008-03-07	2010-09-28	Acraf	Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
KR101581828B1 (ko)	2008-03-07	2015-12-31	아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이	신규한 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1, ｃｘ3ｃｒ1 및 ｐ40의 발현을 기초로 한 질환들의 치료에서 이의 용도
ES2753149T3 (es)	2008-03-07	2020-04-07	Acraf	Derivados de 1-bencil-3-hidroximetilindazol y utilización de los mismos en el tratamiento de enfermedades basadas en la expresión de MCP-1, CXCR1 y P40

2009
- 2009-03-05 KR KR1020107017806A patent/KR101581828B1/ko not_active Expired - Fee Related
- 2009-03-05 PT PT97176382T patent/PT2254869T/pt unknown
- 2009-03-05 GE GEAP200911965A patent/GEP20135912B/en unknown
- 2009-03-05 AU AU2009221083A patent/AU2009221083B2/en not_active Ceased
- 2009-03-05 EA EA201071038A patent/EA018241B1/ru not_active IP Right Cessation
- 2009-03-05 KR KR1020107017445A patent/KR101599867B1/ko not_active Expired - Fee Related
- 2009-03-05 SI SI200931705T patent/SI2254869T1/sl unknown
- 2009-03-05 CN CN200980105556.4A patent/CN101952256B/zh not_active Expired - Fee Related
- 2009-03-05 BR BRPI0907976-9A patent/BRPI0907976A2/pt not_active IP Right Cessation
- 2009-03-05 EP EP17153930.7A patent/EP3181551A1/en not_active Withdrawn
- 2009-03-05 BR BRPI0907977-7A patent/BRPI0907977A2/pt not_active IP Right Cessation
- 2009-03-05 JP JP2010549143A patent/JP5509099B2/ja active Active
- 2009-03-05 GE GEAP200911963A patent/GEP20135983B/en unknown
- 2009-03-05 CA CA2712403A patent/CA2712403C/en not_active Expired - Fee Related
- 2009-03-05 AU AU2009221089A patent/AU2009221089B2/en not_active Ceased
- 2009-03-05 HR HRP20171208TT patent/HRP20171208T1/hr unknown
- 2009-03-05 PL PL09718467T patent/PL2254870T3/pl unknown
- 2009-03-05 MX MX2010009623A patent/MX2010009623A/es active IP Right Grant
- 2009-03-05 PL PL09717638T patent/PL2254869T3/pl unknown
- 2009-03-05 DK DK09718467.5T patent/DK2254870T3/en active
- 2009-03-05 MX MX2010009626A patent/MX2010009626A/es active IP Right Grant
- 2009-03-05 EP EP09718467.5A patent/EP2254870B1/en active Active
- 2009-03-05 DK DK09717638.2T patent/DK2254869T3/en active
- 2009-03-05 EP EP09717638.2A patent/EP2254869B1/en active Active
- 2009-03-05 HU HUE09718467A patent/HUE027098T2/en unknown
- 2009-03-05 SI SI200931404A patent/SI2254870T1/sl unknown
- 2009-03-05 WO PCT/EP2009/052585 patent/WO2009109613A2/en active Application Filing
- 2009-03-05 ES ES09717638.2T patent/ES2637009T3/es active Active
- 2009-03-05 US US12/864,767 patent/US7919518B2/en not_active Expired - Fee Related
- 2009-03-05 ES ES09718467.5T patent/ES2569330T3/es active Active
- 2009-03-05 CN CN200980105073.4A patent/CN101945855B/zh not_active Expired - Fee Related
- 2009-03-05 WO PCT/EP2009/052590 patent/WO2009109618A2/en active Application Filing
- 2009-03-05 SG SG2013013123A patent/SG188177A1/en unknown
- 2009-03-05 JP JP2010549146A patent/JP5509101B2/ja active Active
- 2009-03-05 HR HRP20160462TT patent/HRP20160462T1/hr unknown
- 2009-03-05 LT LTEP09717638.2T patent/LT2254869T/lt unknown
- 2009-03-05 CA CA2712703A patent/CA2712703C/en not_active Expired - Fee Related
- 2009-03-05 EA EA201071040A patent/EA019711B1/ru not_active IP Right Cessation
- 2009-03-05 US US12/865,923 patent/US8835481B2/en not_active Expired - Fee Related
- 2009-03-06 AR ARP090100801A patent/AR070811A1/es unknown
- 2009-03-06 AR ARP090100800A patent/AR070810A1/es unknown
- 2009-05-03 UA UAA201008570A patent/UA105170C2/uk unknown
- 2009-05-03 UA UAA201008883A patent/UA103605C2/uk unknown
2010
- 2010-07-08 IL IL206893A patent/IL206893A0/en not_active IP Right Cessation
- 2010-07-21 IL IL207131A patent/IL207131A/en not_active IP Right Cessation
2011
- 2011-03-07 US US13/041,557 patent/US8283348B2/en not_active Expired - Fee Related
- 2011-10-06 IL IL215579A patent/IL215579A/en not_active IP Right Cessation
2016
- 2016-05-13 CY CY20161100406T patent/CY1117584T1/el unknown
2017
- 2017-08-09 CY CY20171100858T patent/CY1119252T1/el unknown

Also Published As

Publication number	Publication date
US20110003874A1 (en)	2011-01-06
EP2254870A2 (en)	2010-12-01
ES2569330T3 (es)	2016-05-10
US8283348B2 (en)	2012-10-09
CN101945855B (zh)	2014-12-17
HRP20160462T1 (hr)	2016-06-03
KR20100131432A (ko)	2010-12-15
US20110160205A1 (en)	2011-06-30
CY1119252T1 (el)	2018-02-14
AU2009221083B2 (en)	2013-11-28
EA201071038A1 (ru)	2011-02-28
JP5509101B2 (ja)	2014-06-04
CA2712703C (en)	2016-10-11
DK2254869T3 (en)	2017-09-04
WO2009109613A3 (en)	2009-12-10
CN101952256B (zh)	2016-03-16
SI2254869T1 (sl)	2017-10-30
EP2254869A2 (en)	2010-12-01
EP2254870B1 (en)	2016-02-24
GEP20135912B (en)	2013-08-26
CN101945855A (zh)	2011-01-12
EA201071040A1 (ru)	2011-02-28
MX2010009626A (es)	2010-12-20
CA2712403A1 (en)	2009-09-11
IL207131A (en)	2013-02-28
AU2009221089A1 (en)	2009-09-11
US20100311744A1 (en)	2010-12-09
ES2637009T3 (es)	2017-10-10
KR101581828B1 (ko)	2015-12-31
PL2254870T3 (pl)	2016-07-29
PT2254869T (pt)	2017-07-18
HUE027098T2 (en)	2016-08-29
BRPI0907976A2 (pt)	2015-08-04
GEP20135983B (en)	2013-12-10
KR20100133957A (ko)	2010-12-22
HRP20171208T1 (hr)	2017-10-06
SG188177A1 (en)	2013-03-28
CY1117584T1 (el)	2017-04-26
US8835481B2 (en)	2014-09-16
DK2254870T3 (en)	2016-05-17
EP2254869B1 (en)	2017-05-31
EA019711B1 (ru)	2014-05-30
US7919518B2 (en)	2011-04-05
CA2712403C (en)	2017-06-06
IL206893A0 (en)	2010-12-30
EP3181551A1 (en)	2017-06-21
WO2009109618A2 (en)	2009-09-11
CN101952256A (zh)	2011-01-19
AR070810A1 (es)	2010-05-05
IL207131A0 (en)	2010-12-30
WO2009109613A2 (en)	2009-09-11
JP2011513365A (ja)	2011-04-28
SI2254870T1 (sl)	2016-05-31
KR101599867B1 (ko)	2016-03-04
IL215579A (en)	2015-06-30
UA103605C2 (en)	2013-11-11
AU2009221089B2 (en)	2013-12-05
AU2009221083A1 (en)	2009-09-11
JP5509099B2 (ja)	2014-06-04
AR070811A1 (es)	2010-05-05
MX2010009623A (es)	2010-09-28
EA018241B1 (ru)	2013-06-28
CA2712703A1 (en)	2009-09-11
UA105170C2 (en)	2014-04-25
LT2254869T (lt)	2017-08-10
BRPI0907977A2 (pt)	2015-08-04
JP2011513367A (ja)	2011-04-28
WO2009109618A3 (en)	2009-12-10
IL215579A0 (en)	2011-11-30

Publication	Publication Date	Title
PL2254869T3 (pl)	2017-10-31	Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40
SI2170848T1 (sl)	2015-01-30	Derivati pirazinona in njihova uporaba pri zdravljenju bolezni pljuč
IL207277A (en)	2015-03-31	New Annotations of 1 - Benzyl - 3 - Hydroxymethylindazole
NO20081842L (no)	2008-07-08	Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
AP2965A (en)	2014-09-30	Therapeutic compositions and the use thereof
EP2219448A4 (en)	2011-10-12	THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
AP2490A (en)	2012-10-04	Therapeutic compositions and the use thereof
SI2262777T1 (sl)	2016-05-31	1-benzil-3-hidroksimetilindazolni derivati in njihova uporaba pri zdravljenju bolezni, ki temeljijo na ekspresiji MCP-1 in CX3CR1
SI2148667T1 (sl)	2013-12-31	Uporaba derivatov cikloheksanheksola pri zdravljenju okularnih bolezni
PL2012805T3 (pl)	2014-01-31	Kompozycja lecznicza i jej zastosowanie
ZA201108106B (en)	2013-07-31	Use of phthalimide derivatives in the treatment of diseases
IL201426A0 (en)	2010-05-31	Drug combination and its use in the treatment of muscle loss
ZA201001207B (en)	2010-10-27	Therapeutic formulations for the treatment of cold and flu-like symptoms
IL193943A0 (en)	2009-08-03	The use of beta- aminoalcohols for the treatment of inflammatory disorders and pain
ZA200904755B (en)	2010-09-29	Use of epothilones in the treatment of osteoporosis and related diseases
IL193944A0 (en)	2009-08-03	The use beta-aminoalcohols for the treatment of inflammatory disorders and pain
PL2224934T3 (pl)	2012-12-31	Zastosowanie osteoblastów w leczeniu zapalnych chorób reumatycznych
HK1145323A (en)	2011-04-15	1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
ZA200909073B (en)	2010-09-29	Pyrazinone derivatives and their use in the treatment of lung diseases
IL194275A0 (en)	2009-09-22	Use of digitalis-like compounds in the treatment of affective disorders
IL202502A0 (en)	2011-08-01	Agents for the treatment of inflammatory diseases and methods of using same